A director at Pulse Biosciences Inc sold 50,000 shares at 17.420USD and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
AMREP Reports Second Quarter Fiscal 2025 Results HAVERTOWN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $4,042,000, or $0.75 per diluted share, for its 2025 fiscal second quarter ended October 31, 2024 compared to net income of $1,108,000, or $0.21 per diluted share, for the same period of the prior year. For the first six months of 2025, AMREP had net income of $8,106,000, or $1.51 per diluted share, compared to net income of $2,454,000, or $0.46 per diluted share, for the same period of 2024. Revenues were $11,906,000 and $30,997,000 ...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Erasca Reports Third Quarter 2024 Business Updates and Financial Results Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution across potentially best-in-class RAS targeting franchise; planned IND submissions on track Robust balance sheet with cash, cash equivalents, and marketable securities of $463 million as of September 30, 2024, is expected to fund operations into H1 2027 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eras...
Shoals Technologies Group, Inc. Reports Financial Results for Third Quarter 2024 – Secures Favorable Initial Ruling in ITC Case Against Voltage, LLC – – Quarterly Revenue of $102.2 million – – Gross Profit Percentage of 24.8% and Adjusted Gross Profit Percentage of 37.9% – – Net Loss of $0.3 million – – Adjusted EBITDA of $24.5 million – – Raises Midpoint of Full-Year Revenue Outlook – PORTLAND, Tenn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of system (“EBOS”) s...
Erasca to Present at Upcoming Investor Conferences SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings. Guggenheim Securities Healthcare Innovation Conference (November 11 – 13, 2024)Location: InterContinental Hotel, Boston, MAFormat: Fireside Chat Date a...
Shoals Technologies Group, Inc. Announces Participation in Upcoming Investor Events PORTLAND, Tenn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals”), a global leader in electrical balance of system (“EBOS”) solutions for the energy transition market, announced today its participation in the following upcoming investor events: November 14, 2024: Jefferies Virtual Fireside Chat Shoals’ CEO Brandon Moss, CFO Dominic Bardos, and VP of Finance and Investor Relations Matt Tractenberg will participate in a fireside chat with covering analyst Julien Dumoulin-Smith....
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib plus trametinib reinforce therapeutic potential in NRASm melanoma and further support ongoing Phase 3 SEACRAFT-2 trial SEACRAFT-2 has potential for approval based on alignment with US and European regulatory agencies on path for tissue-specific indication in melanoma; Stage 1 randomized data expected in 2025 Rapid progress across RAS targeting franchise; planned IND submissions remain on track Erasca to host investor event today at 8:30 AM Eastern Tim...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.